Re-expression of CAMK2N1 in prostate cancer may provide clinical benefits to patients; however, further studies are warranted to determine the molecular mechanisms link between CAMK2N1 and androgen receptor signaling in prostate cancer. The gene discussed is AR; the disease is prostate carcinoma.